OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer

OKYO Pharma announced that its Chief Scientific Officer, Raj Patil, PhD, increased his holdings by purchasing 3,363 ordinary shares, bringing his total to 20,030 shares. The clinical-stage biopharmaceutical company is developing therapies for neuropathic corneal pain and anterior segment eye diseases, with a global Phase 3 clinical trial planned for later this year.